Overview
- Vanda said it expects to launch Nereus in the coming months.
- The drug, also known as tradipitant, works by blocking a brain receptor linked to nausea and vomiting.
- Approval was supported by two placebo-controlled studies in which the treatment outperformed placebo on vomiting prevention.
- Existing options for motion-related symptoms include the scopolamine patch Transderm Scop and over-the-counter products Bonine and Dramamine.
- The FDA lifted a prior partial clinical hold on tradipitant on December 4 after classifying motion sickness as an acute condition.